An Open-lable, Randomized, Multi center, Phase III Study to Compare the Saftey and Efficacy of TKI258 Versus Sorafenib in Patients with Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor Therapies"
2022-06-29
عنوان الدراسة
An Open-lable, Randomized, Multi center, Phase III Study to Compare the Saftey and Efficacy of TKI258 Versus Sorafenib in Patients with Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor Therapies"
داعم الدراسة
Novartis
دواء الدراسة
TKI258 / Sorafenib
رقم بروتوكول الدراسة
CTKI258A2302
حالة الدراسة
Completed
موقع الدراسة
KFSH & RC-R
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。